RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention

24 June 2026

Professor Paul Kellam Elected Fellow of the Academy of Medical Sciences

21 May 2026

Welcoming new talent: Strengthening our mission through research and innovation

4 August 2025

Advancing global health: Our team at the BIO international convention 2025

12 June 2025

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals

9 January 2025

RQ Biotechnology Ltd. Celebrates Milestone with Grant of GB Patent Covering its Licensed Clinical-Stage Antibody for the Prevention and Treatment of COVID-19

18 March 2024